Neutropenia (low white blood cell count) is a common side effect of chemotherapy in patients with cancer, with sepsis being a potential consequence. The timely identification and treatment of sepsis is paramount to the success of therapy.
Having the ability to rapidly make an assessment of sepsis risk in neutropenic patients would be a significant improvement in how we manage these patients. Next Generation Sequencing (NGS) has potential utility as a biomarker of the risk of sepsis in neutropenic patients and could be used to fill this unmet need.
- In Development
- To be Decided